- Home
- BTU vs KNSA Comparison
BTU vs KNSA Comparison
Compare BTU & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTU | KNSA |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United Kingdom |
| Employees | 6600 | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.4B |
| IPO Year | 2001 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BTU | KNSA |
|---|---|---|
| Price | $32.68 | $46.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $31.71 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 2.5M | 580.2K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | ★ $3,861,500,000.00 | $677,564,000.00 |
| Revenue This Year | $18.45 | $38.01 |
| Revenue Next Year | $5.84 | $17.42 |
| P/E Ratio | ★ N/A | $62.41 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $9.61 | $18.26 |
| 52 Week High | $39.95 | $49.12 |
Technical Indicators
Market Signals| Indicator | BTU | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 57.86 |
| Support Level | $32.29 | $40.47 |
| Resistance Level | $39.18 | $49.12 |
| Average True Range (ATR) | 1.78 | 2.17 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 36.66 | 71.13 |
Price Performance
Historical ComparisonAbout BTU Peabody Energy Corporation
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan, and other regions.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.